Cerliponase alfa ▼ is not registered in all countries, and where it is registered the content of its indication along with other content may vary.
Please refer to your local prescribing information before prescribing cerliponase alfa.

▼ This medicinal product is subject to additional monitoring, special reporting is required in relation to adverse reactions. Email us at medinfo@bmrn.com for further details.

This website is sponsored and funded by BioMarin for healthcare professionals only.
Image of LYNK web banner

LYNK- Lysosomal & NCL Insights and Knowledge-sharing Network

This global initiative connects specialists, treatment centres, and referral networks together to optimise long term care for patients with NCLs.

Our mission is to share best practices, align care standards, and optimise patient pathways while fostering thought leadership and advancing rare disease education and care.

Through a series of interactive forums, educational resources, and expert-led webinars, LYNK provides a space to:
Collaborate with peers and treatment centres to harmonise standards of care
Share clinical experiences, challenges and evolving best practice
Learn from real-world multidisciplinary perspectives
Advance long-term outcomes for children living with NCLs

Together, we can build stronger connections, improve patient pathways and support optimal outcomes for patients with NCL worldwide.

Be part of the conversation. Be part of the change.

*This programme is sponsored and funded by BioMarin and will contain information on BioMarin products. It is a promotional programme intended exclusively for healthcare professionals.

Latest Resources

Download or watch the latest from the LYNK Network

Resource

Welcome to LYNK

Connecting healthcare professionals together to collaborate, learn new insights and transform NCL care. Join now to explore.